Korea’s Dong-A Wins WHO Prequalification For TB Generic Of Lilly’s Seromycin As Firm Moves Up Value Chain
This article was originally published in PharmAsia News
Executive Summary
WHO prequalification clears path for Korea’s Dong-A to move from an API supplier of cycloserine to an exporter of finished products.